Loading ...
Sorry, an error occurred while loading the content.

Fwd: NATAP: AASLD Reports Hep B & Hep C

Expand Messages
  • claudine intexas
    Subject: NATAP: AASLD Reports Hep B & Hep C NATAP http://natap.org/ _______________________________________________ NATAP http://www.natap.org AASLD American
    Message 1 of 1 , Nov 30, 2005
    • 0 Attachment
      Subject: NATAP: AASLD Reports Hep B & Hep C

      NATAP http://natap.org/
      _______________________________________________
      NATAP http://www.natap.org

      AASLD
      American Association For The Study of Liver Diseases
      November 11-15, 2005 San Francisco

      Hepatitis B Articles
      Â
      • Normal ALT & Low HBV-DNA May Be Risk for Cirrhosis & HCC (11/28/05)
      Â
      • Serum Leptin Level Associated with Severity of Liver Fibrosis & Decreased After Pegasys Treatment in Chronic Hepatitis B (11/28/05)
      Â
      • Low Rate of Viral Rebound Seen in HBV Patients Treated With Entecavir (11/28/05)
      Â
      • Entecavir 2 Years Study Results in HBeAg+ HBV+ Patients (study ETV-22) (11/16/05)
      Â
      • Five-Year Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting (11/15/05)
      Â
      • SEVERE IMPAIRMENT IN QUALITY OF LIFE IN HIV+ WITH HCV BUT NOT WITH HBV (11/14/05)
      Â
      • BARACLUDE (entecavir) TWO-YEAR DATA ANALYSIS DID NOT DETECT EMERGENCE OF RESISTANCE IN NUCLEOSIDE-NAIVE CHRONIC HEPATITIS B PATIENTS (11/14/05)
      Â

      Hepatitis C Articles
      Â
      • A Phase 2 Study of Albuferon in Combination with Ribavirin in non-responders to proir interferon therapy for chronic Hepatitis C (11/28/05)
      Â
      • NM283 +Pegasys for Nonresponders: phase II 12 weeks (11/28/05)
      Â
      • Consensus IFN+ IFN Gamma-1b in African-American Peg Nonresponders (11/28/05)
      Â
      • Consensus Interferon + Ribavirin SVRs in Coinfected (11/28/05)
      Â
      • Consensus Interferon: study results at AASLD (11/17/05)
      Â
      • Albuferon-Alpha (Albumin-Interferon Alpha) (11/17/05)
      Â
      • REPEAT Study: Non-responders to ≥12 weeks' treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin (11/15/05)
      Â
      • Albuferon + Ribavirin in PegIFN Nonresponders: phase 2 study (11/15/05)
      Â
      • SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders (11/15/05)
      Â
      • VX-950 Hep C Protease Inhibitor (11/15/05)
      Â
      • Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)
      Â
      • Liver Transplant Articles AASLD (11/14/05)
      Â
      • Study Evaluations of Non-Invasive Fibrosis Tests AASLD (11/14/05)
      Â
      • Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)
      Â
      • LIVER HISTOLOGY IN HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS (11/14/05)
      Â
      • Hispanics Developed Cirrhosis More Quickly Due to the presence of Fatty Liver & Diabetes (11/14/05)
      Â
      • IMPACT OF CAFFEINE CONSUMPTION ON ALT AND HISTOLOGICAL ACTIVITY IN PATIENTS WITH CHRONIC ACTIVE HCV (11/14/05)
      Â
      • CANNABINOIDS BLOCK INTERFERON-MEDIATED SUPPRESSION OF HEPATITIS C VIRUS (HCV) REPLICATION (11/14/05)
      Â
      • CRYOGLOBULINEMIA IS ASSOCIATED WITH STEATOSIS AND FIBROSIS IN CHRONIC HCV (11/14/05)
      Â
      • INDEPENDENT VALIDATION AND COMPARISON WITH FIBROSCAN, FIBROTEST AND LIVER BIOPSY OF CLINICAL GLYCOMICS FOR THE NON INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV (11/14/05)
      Â
      • COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HCV IN PATIENTS COINFECTED WITH HIV (11/14/05)
      Â
      • COFFEE DRINKING DECREASES THE RISK OF CHRONIC LIVER DISEASE IN THE UNITED STATES POPULATION (11/14/05)
      Â
      • African-American patients had fewer office visits and were less likely to return for a second office visit (11/14/05)
      Â
      • VIROLOGICAL AND HISTOLOGICAL FEATURES OF HCV IN PATIENTS WITH NORMAL ALT: RESULTS OF A TEN YEAR PROPSECTIVE FOLLOW-UP STUDY (11/14/05)
      Â
      • FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE (11/14/05)
      Â
      • 2.2% Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+ (11/14/05)
      Â
      • Telbivudine (LdT) Phase 3 One Year Study Results (11/14/05)
      Â
      • FIBROSCAN, MONITORING LIVER STIFFNESS: A NEW TOOL TO MEASURE LIVER FIBROSIS DURING THERAPY (11/14/05)
      Â
      • IS LIVER BIOPSY JUSTIFIED IN HEPATITIS C GENOTYPE 2 AND 3? (11/14/05)
      Â
      • ON TREATMENT VIROLOGICAL RESPONSE OF 70% IN 100 PATIENTS TREATED WITH COMBINATION ANTIVIRAL THERAPY FOR RECURRENT HCV FOLLOWING LIVER TRANSPLANTATION (11/14/05)
      Â
      • MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A (Pegasys) AND RIBAVIRIN AFTER LIVER TRANSPLANTATION:ONE-YEAR REPORT (11/14/05)
      Â
      • RECURRENT HEPATITIS C IS A RISK FACTOR FOR POOR OUTCOME AFTER LIVER RETRANSPLANTATION (11/14/05)
      Â
      • PREDICTING OUTCOME IN PATIENTS WITH HCV AFTER OLT: A 15-YEARS FOLLOW-UP (11/14/05)
      Â
      • LONG TERM RESULTS AFTER THERAPY WITH PEGYLATED INTERFERON ALPHA 2A (PEGASYS) IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS (11/14/05)
      Â
      • THE PERFORMANCE OF APRI FOR THE DIAGNOSIS OF SIGNIFICANT HEPATIC FIBROSIS IS IMPROVED BY A SIMPLE MODIFICATION (11/14/05)
      Â
      • Diabetes Death & Complications May triple in Next 20 years (11/11/05)
      Â
      HIV Articles
      Â
      • Troglitazone significantly reduced tumor growth in vivo, and caused tumor regression in liver cells (11/14/05)
      Â
      • 24% with HCV Are HIV+ at NYC Hospitals Studied (11/14/05)
      Â
      • Liver Disease The Leading Cause of Death in HIV: Hepatitis screening campaign launched. AASLD Liver Conference Starts Nov 10 in SF (11/11/05)

      • EVIDENCE FOR SEXUAL TRANSMISSION OF HCV IN RECENT EPIDEMIC IN HIV-INFECTED MEN IN SOUTHEAST ENGLAND (11/14/05)




      ----------

      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.